With the support of RxCelerate, X01 developed Ichorcumab, a recombinant human antibody that is now entering Phase 2 trials for the prevention and treatment of thrombosis. Ichorcumab was designed to mimic the activity of an antibody identified in a patient that produced an anticoagulated state without predisposition to bleeding.
RxCelerate provided scientific leadership, developed and executed all pharmacology models and provided expert oversight of the regulatory studies that supported the successful IND filing.
XO1 was acquired by Janssen Pharmaceuticals, Inc. and the asset is now progressing to proof-of-concept clinical trials.
RxCelerate was instrumental in the success of XO1. They should be your first port of call for those critical experiments upon which the value and decision-making of your company or programme depend